publication . Article . 2021

Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients

Geoffroy Hariri; Tomas Urbina; Sandie Mazerand; Naïke Bigé; Jean-Luc Baudel; Hafid Ait-Oufella;
Open Access English
  • Published: 01 Dec 2021
  • Publisher: HAL CCSD
  • Country: France
Abstract
International audience
Persistent Identifiers
Subjects
ACM Computing Classification System: ComputingMilieux_MISCELLANEOUS
free text keywords: [SDV]Life Sciences [q-bio], Critical Care and Intensive Care Medicine, Research Letter, Critical illness, Coronavirus disease 2019 (COVID-19), Atrial fibrillation, medicine.disease, medicine, Landiolol, medicine.drug, Rate control, Intensive care medicine, medicine.medical_specialty, Critically ill, business.industry, business, Patient safety, Prospective cohort study, lcsh:Medical emergencies. Critical care. Intensive care. First aid, lcsh:RC86-88.9
Related Organizations

1. Steinberg I, Brogi E, Pratali L, Trunfio D, Giuliano G, Bignami E, Forfori F. Atrial fibrillation in patients with septic shock: a one ‑ year observational pilot study. Turk J Anaesthesiol Reanim. 2019;47(3):213-9.

2. Meierhenrich R, Steinhilber E, Eggermann C, Weiss M, Voglic S, Bogelein D, Gauss A, et al. Incidence and prognostic impact of new‑ onset atrial ifbrillation in patients with septic shock: a prospective observational study. Crit Care. 2010;14(3):R108.

3. Schmittinger CA, Torgersen C, Luckner G, Schroder DC, Lorenz I, Dunser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950-8.

4. Sasao J, Tarver SD, Kindscher JD, Taneyama C, Benson KT, Goto H. In rabbits, landiolol, a new ultra‑short ‑acting beta‑blocker, exerts a more potent negative chronotropic eefct and less eefct on blood pressure than esmolol. Can J Anaesth. 2001;48(10):985-9.

5. Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, et al. Eficacy and safety of landiolol, an ultra‑short ‑acting beta1‑selective antagonist, for treatment of sepsis‑related tachyarrhythmia (J‑Land 3S): a multicentre, open‑label, randomised controlled trial. Lancet Respir Med. 2020;9:863-72.

6. Matsuishi Y, Mathis BJ, Shimojo N, Kawano S, Inoue Y. Evaluating the therapeutic eficacy and safety of landiolol hydrochloride for manage ‑ ment of arrhythmia in critical settings: review of the literature. Vasc Health Risk Manag. 2020;16:111-23.

Any information missing or wrong?Report an Issue